BACKGROUND: Over the past two decades, the global incidence of gout has markedly increased, affecting people worldwide. Considering the side effects of xanthine oxidase (XO) inhibitor drugs (e.g. allopurinol and febuxostat) used in the treatment of hyperuricemia and gout, the potential application of phytochemicals has been widely studied. In addition, XO also takes part in the elimination of certain drugs, including 6-mercaptopurine. In the current explorative study, we aimed to examine the potential effects of tea catechins, resveratrol, silymarin flavonolignans and some of their conjugated metabolites on XO-catalyzed xanthine and 6-mercaptopurine oxidation, applying in vitro assays and modeling studies. RESULTS: Catechins, resveratrol and resveratrol conjugates exerted no or only weak inhibitory effects on XO. Silybin A, silybin B and isosilybin A were weak, silychristin was a moderate, while 2,3-dehydrosilychristin was a potent inhibitor of the enzyme. Sulfate metabolites of silybin A, silybin B and isosilybin A were considerably stronger inhibitors compared to the parent flavonolignans, and the sulfation of 2,3-dehydrosilychristin slightly increased its inhibitory potency. Silychristin was the sole flavonolignan tested, where sulfate conjugation decreased its inhibitory effect. CONCLUSION: 2,3-Dehydrosilychristin seems to be a promising candidate for examining its in vivo antihyperuricemic effects, because both the parent compound and its sulfate conjugate are highly potent inhibitors of XO. © 2024 The Author(s). Journal of the Science of Food and Agriculture published by John Wiley & Sons Ltd on behalf of Society of Chemical Industry.

Department of Laboratory Medicine Medical School University of Pécs Pécs Hungary

Department of Pharmaceutics and Central Clinical Pharmacy Faculty of Pharmacy University of Pécs Pécs Hungary

Department of Pharmacognosy Faculty of Pharmacy University of Pécs Pécs Hungary

Institute of Microbiology of the Czech Academy of Sciences Prague Czech Republic

Molecular Medicine Research Group János Szentágothai Research Centre University of Pécs Pécs Hungary

National Laboratory for Drug Research and Development Budapest Hungary

Pharmacoinformatics Unit Department of Pharmacology and Pharmacotherapy Medical School University of Pécs Pécs Hungary

Zobrazit více v PubMed

Musial C, Kuban‐Jankowska A and Gorska‐Ponikowska M, Beneficial properties of green tea catechins. Int J Mol Sci 21:1744 (2020). PubMed PMC

van het Hof KH, Kivits GA, Weststrate JA and Tijburg LB, Bioavailability of catechins from tea: the effect of milk. Eur J Clin Nutr 52:356–359 (1998). 10.1038/sj.ejcn.1600568. PubMed DOI

Widlansky ME, Duffy SJ, Hamburg NM, Gokce N, Warden BA, Wiseman S PubMed DOI

Khattar S, Khan SA, Zaidi SAA, Darvishikolour M, Farooq U, Naseef PP PubMed PMC

Berman AY, Motechin RA, Wiesenfeld MY and Holz MK, The therapeutic potential of resveratrol: a review of clinical trials. NPJ Precis Oncol 1:35 (2017). 10.1038/s41698-017-0038-6. PubMed DOI PMC

Walle T, Bioavailability of resveratrol: resveratrol bioavailability. Ann N Y Acad Sci 1215:9–15 (2011). 10.1111/j.1749-6632.2010.05842.x. PubMed DOI

Yu C, Shin YG, Chow A, Li Y, Kosmeder JW, Lee YS PubMed DOI

Wenzel E, Soldo T, Erbersdobler H and Somoza V, Bioactivity and metabolism of PubMed DOI

Patel KR, Brown VA, Jones DJL, Britton RG, Hemingway D, Miller AS PubMed DOI PMC

Boocock DJ, Faust GES, Patel KR, Schinas AM, Brown VA, Ducharme MP PubMed DOI

Brown VA, Patel KR, Viskaduraki M, Crowell JA, Perloff M, Booth TD PubMed DOI PMC

Abenavoli L, Izzo AA, Milić N, Cicala C, Santini A and Capasso R, Milk thistle ( PubMed DOI

Chambers CS, Holeckova V, Petraskova L, Biedermann D, Valentova K, Buchta M PubMed DOI

Křen V and Valentová K, Silybin and its congeners: from traditional medicine to molecular effects. Nat Prod Rep 39:1264–1281 (2022). 10.1039/d2np00013j. PubMed DOI

Hoh C, Boocock D, Marczylo T, Singh R, Berry DP, Dennison AR PubMed DOI

Lněničková K, Vrba J, Kosina P, Papoušková B, Mekadim C, Mrázek J DOI

Brinda BJ, Zhu HJ and Markowitz JS, A sensitive LC–MS/MS assay for the simultaneous analysis of the major active components of silymarin in human plasma. J Chromatogr B 902:1–9 (2012). 10.1016/j.jchromb.2012.06.003. PubMed DOI

Saller R, Meier R and Brignoli R, The use of silymarin in the treatment of liver diseases. Drugs 61:2035–2063 (2001). 10.2165/00003495-200161140-00003. PubMed DOI

He Q, Mok TN, Sin TH, Yin J, Li S, Yin Y PubMed DOI PMC

Yang S, Liu H, Fang XM, Yan F and Zhang Y, Signaling pathways in uric acid homeostasis and gout: from pathogenesis to therapeutic interventions. Int Immunopharmacol 132:111932 (2024). PubMed

Schmidt HM, Kelley EE and Straub AC, The impact of xanthine oxidase (XO) on hemolytic diseases. Redox Biol 21:101072 (2019). PubMed PMC

Harrison R, Structure and function of xanthine oxidoreductase: where are we now? Free Radic Biol Med 33:774–797 (2002). 10.1016/s0891-5849(02)00956-5. PubMed DOI

Berry CE and Hare JM, Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol 555:589–606 (2004). 10.1113/jphysiol.2003.055913. PubMed DOI PMC

Galbusera C, Orth P, Fedida D and Spector T, Superoxide radical production by allopurinol and xanthine oxidase. Biochem Pharmacol 71:1747–1752 (2006). 10.1016/j.bcp.2006.02.008. PubMed DOI

Mehmood A, Ishaq M, Zhao L, Safdar B, Rehman A, Munir M PubMed DOI

Naeem A, Ming Y, Pengyi H, Jie KY, Yali L, Haiyan Z PubMed DOI

Mohos V, Pánovics A, Fliszár‐Nyúl E, Schilli G, Hetényi C, Mladěnka P PubMed PMC

Balázs O, Dombi Á, Zsidó BZ, Hetényi C, Valentová K, Vida RG PubMed

Yuan M, Liu Y, Xiao A, Leng J, Liao L, Ma L PubMed DOI PMC

Rashidinejad A, Birch EJ and Everett DW, Green tea catechins suppress xanthine oxidase activity in dairy products: an improved HPLC analysis. J Food Compos Anal 48:120–127 (2016). 10.1016/j.jfca.2016.03.001. DOI

Zhang G, Zhu M, Liao Y, Gong D and Hu X, Action mechanisms of two key xanthine oxidase inhibitors in tea polyphenols and their combined effect with allopurinol. J Sci Food Agric 102:7195–7208 (2022). 10.1002/jsfa.12085. PubMed DOI

Huang XF, Li HQ, Shi L, Xue JY, Ruan BF and Zhu HL, Synthesis of resveratrol analogues, and evaluation of their cytotoxic and xanthine oxidase inhibitory activities. Chem Biodivers 5:636–642 (2008). 10.1002/cbdv.200890059. PubMed DOI

Agbadua OG, Kúsz N, Berkecz R, Gáti T, Tóth G and Hunyadi A, Oxidized resveratrol metabolites as potent antioxidants and xanthine oxidase inhibitors. Antioxidants 11:1832 (2022). PubMed PMC

Varga Z, Seres I, Nagy E, Ujhelyi L, Balla G, Balla J PubMed DOI

Pauff JM and Hille R, Inhibition studies of bovine xanthine oxidase by luteolin, silibinin, quercetin, and curcumin. J Nat Prod 72:725–731 (2009). 10.1021/np8007123. PubMed DOI PMC

Mottet C, Schoepfer AM, Juillerat P, Cosnes J, Froehlich F, Kessler‐Brondolo V PubMed DOI

McLeod HL, Clinically relevant drug‐drug interactions in oncology. Br J Clin Pharm 45:539–544 (1998). 10.1046/j.1365-2125.1998.00719.x. PubMed DOI PMC

Valentová K, Purchartová K, Rydlová L, Roubalová L, Biedermann D, Petrásková L PubMed PMC

Faisal Z, Mohos V, Fliszár‐Nyúl E, Valentová K, Káňová K, Lemli B PubMed

Balázs O, Dombi Á, Zsidó BZ, Hetényi C, Vida RG and Poór M, Probing the interactions of 31 mycotoxins with xanthine oxidase: alternariol, alternariol‐3‐sulfate, and PubMed PMC

Hu T and Liu Y, Probing the interaction of cefodizime with human serum albumin using multi‐spectroscopic and molecular docking techniques. J Pharm Biomed Anal 107:325–332 (2015). 10.1016/j.jpba.2015.01.010. PubMed DOI

Wang T, Zeng LH and Li DL, A review on the methods for correcting the fluorescence inner‐filter effect of fluorescence spectrum. Appl Spectrosc Rev 52:883–908 (2017). 10.1080/05704928.2017.1345758. DOI

Najaran A, Divsalar A, Saboury AA and Roodbari NH, Probing the interaction of newly synthesized Pt(II) complex on human serum albumin using competitive binding site markers. J Fluoresc 29:827–835 (2019). 10.1007/s10895-019-02383-3. PubMed DOI

Mohammadgholi A, Leilabadi‐Asl A, Divsalar A and Eslami‐Moghadam M, Multi‐spectroscopic studies of the interaction of new synthesized platin complex with human carrier protein of serum albumin. J Biomol Struct Dyn 39:1506–1511 (2021). 10.1080/07391102.2020.1745690. PubMed DOI

Chaves OA, dos Santos Oliveira CHC, Ferreira RC, Cesarin‐Sobrinho D, da Hora Machado AE and Netto‐Ferreira JC, Synthetic dimethoxyxanthones bind similarly to human serum albumin compared with highly oxygenated xanthones. Chem Phys Impact 8:100411 (2024).

Mohos V, Fliszár‐Nyúl E, Lemli B, Zsidó BZ, Hetényi C, Mladěnka P PubMed PMC

Csenki Z, Bartók T, Bock I, Horváth L, Lemli B, Zsidó BZ PubMed PMC

Pauff JM, Cao H and Hille R, Substrate orientation and catalysis at the molybdenum site in xanthine oxidase. J Biol Chem 284:8760–8767 (2009). 10.1074/jbc.M804517200. PubMed DOI PMC

Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK DOI

Zsidó BZ, Börzsei R, Szél V and Hetényi C, Determination of ligand binding modes in hydrated viral ion channels to foster drug design and repositioning. J Chem Inf Model 61:4011–4022 (2021). 10.1021/acs.jcim.1c00488. PubMed DOI PMC

Zsidó BZ, Balog M, Erős N, Poór M, Mohos V, Fliszár‐Nyúl E PubMed PMC

Mahomoodally MF, Coodian K, Hosenally M, Zengin G, Shariati MA, Abdalla AN PubMed DOI

Mohos V, Fliszár‐Nyúl E and Poór M, Inhibition of xanthine oxidase‐catalyzed xanthine and 6‐mercaptopurine oxidation by flavonoid aglycones and some of their conjugates. Int J Mol Sci 21:3256 (2020). PubMed PMC

Petrásková L, Káňová K, Biedermann D, Křen V and Valentová K, Simple and rapid HPLC separation and quantification of flavonoid, flavonolignans, and 2,3‐dehydroflavonolignans in silymarin. Foods 9:116 (2020). PubMed PMC

Tvrdý V, Pourová J, Jirkovský E, Křen V, Valentová K and Mladěnka P, Systematic review of pharmacokinetics and potential pharmacokinetic interactions of flavonolignans from silymarin. Med Res Rev 41:2195–2246 (2021). 10.1002/med.21791. PubMed DOI